The number of ADHD diagnoses in Estonia has surged in recent years, from nearly 3,500 in 2020 to over 12,800 in 2024, driving ...

Attention-deficit/hyperactivity disorder (ADHD) affects 3%–5% of children and about 2.5% of adults, though prevalence varies ...

Prescriptions for methylphenidate, a central nervous system stimulant primarily used to treat attention deficit hyperactivity ...

There are concerns that the drugs are being misused for academic performance. Read more at straitstimes.com. Read more at ...

Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...

After evaluating scans of almost 5,800 children with and without attention deficit disorder, US researchers discovered that ...

German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...

Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

As of Friday, January 09, Collegium Pharmaceutical, Inc.’s COLL share price has dipped by 6.84%, which has investors questioning if this is right time to buy.

Children with attention-deficit/hyperactivity disorder who receive methylphenidate may be at an increased risk of having a ...